BIOCYTOGEN
8.3.2023 14:26:40 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sub-Q Bionics Announces Licensing Agreement to Advance Lymphedema Care17.3.2026 14:46:00 CET | Press release
Sub‑Q Bionics, a medical device company developing an innovative implantable lymphatic drainage system designed to help patients living with lymphedema better manage their symptoms, today announced a licensing agreement with Mayo Clinic. Through the agreement, Sub-Q Bionics has licensed clinical know-how from Mayo Clinic related to reconstructive and lymphatic surgery. As part of this collaboration, Vahe Fahradyan, M.D., a plastic and reconstructive surgeon with expertise in lymphatic surgery, plans to work with Sub-Q Bionics as a clinical collaborator supporting the company’s ongoing development activities. Lymphedema is a chronic condition caused by impaired lymphatic drainage that can lead to persistent swelling, discomfort, and reduced mobility. It commonly occurs following cancer treatment, particularly among breast cancer survivors. Sub-Q Bionics is developing the world’s first implantable bionic lymphatic drainage system designed to assist with movement of lymphatic fluid and he
TrailRunner International Names Alden Mitchell as President of TrailRunner Sports17.3.2026 14:03:00 CET | Press release
Proven global business leader brings more than two decades of experience in sports, media, and technology with a track record of success at iconic brands including Uber, Viacom, Discovery, collegiate conferences, and Stanford University TrailRunner International today announced that Alden Mitchell has been named President of TrailRunner Sports, the firm’s global sports advisory business. Most recently Chief Operating Officer of Stanford Athletics, Mitchell will accelerate the growth and expansion of TrailRunner Sports, which was established to provide strategic business advisory and communications support to global sports clients spanning leagues, teams, conferences, educational institutions, ownership groups, athletes, investors, and brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317576708/en/ Alden Mitchell, President of TrailRunner Sports Since its launch in 2023, TrailRunner Sports has seen significant growth
Qualcomm Increases Quarterly Cash Dividend and Announces New $20 Billion Stock Repurchase Authorization17.3.2026 14:00:00 CET | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that its Board of Directors has approved an increase in the Company’s quarterly cash dividend from $0.89 to $0.92 per share of common stock. This dividend increase will be effective for quarterly dividends payable after March 26, 2026, and will raise the annualized dividend payout to $3.68 per share of common stock. Additionally, the Board of Directors has approved, effective immediately, a new $20.0 billion stock repurchase authorization. The new stock repurchase authorization is in addition to the Company’s stock repurchase program announced in November 2024, which has approximately $2.1 billion of repurchase authority remaining. The new stock repurchase program has no expiration date. The timing of stock repurchases and the number of shares of common stock to be repurchased will depend upon prevailing market conditions and other factors. Repurchases under this program may be commenced or suspended from time-to-time at the Company’
Lwart Environmental Solutions Expands Long-Standing Relationship with Rimini Street, Consolidating Support for VMware and SAP to Regain Control of Licensing and Roadmap Decisions17.3.2026 14:00:00 CET | Press release
Brazilian oil re‑refinery avoids forced upgrades, stabilizes core systems and redirects IT savings toward business innovation Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Lwart Environmental Solutions, one of the world’s leading oil re-refineries and industrial sustainability organizations, has expanded its long-time partnership with Rimini Street. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317697393/en/ Lwart Environmental Solutions Expands Long-Standing Relationship with Rimini Street, Consolidating Support for VMware and SAP to Regain Control of Licensing and Roadmap Decisions By switching to Rimini Street for SAP and VMware support, Lwart has taken direct control of its software licensing, upgrade and technology roadmap decisions, eliminating vendor-driven timelines and cost es
Lenovo Partners with Eva Longoria to Launch Global Search for Business “Twins”17.3.2026 14:00:00 CET | Press release
Backing Every Business initiative pairs founders with mentorship, grants and AI-powered technology - because no small business owner should build alone.Eva Longoria is ready to be your “business twin;” entrepreneurs worldwide can apply to be mentored directly by her. Applications are open now. Lenovo today launches Backing Every Business, a new global initiative designed to close the support gap facing small businesses. In partnership with actress, entrepreneur and investor Eva Longoria, founders around the world can apply for grant funding, AI-enabled technology and one-to-one mentorship, including from Longoria herself. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317068350/en/ Small and medium-sized businesses fuel the world’s economy, representing approximately 90% of all businesses, 70% of employees and 50% of global GDP, according to the World Economic Forum. Their impact is anything but small, yet many founders s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom